Trials / Active Not Recruiting
Active Not RecruitingNCT04000906
PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis
A Phase Ib Trial of Intraperitoneal Cisplatin and Nab-paclitaxel Administered by Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Advanced Malignancies Confined to the Peritoneal Cavity
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- University Hospital, Geneva · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase Ib trial including investigating the combination of nab-paclitaxel and cisplatin in patients diagnosed with peritoneal carcinomatosis related to pancreatic, oeso-gastric, ovarian cancer or primitive peritoneal mesothelioma.
Detailed description
Phase Ib trial investigating the combination of intraperitoneal Cisplatin (10.5 mg/m2) and Nab-paclitaxel (escalated dose from 7.5 mg/m2 to 70 mg/m2) administered by pressurized intraperitoneal aerosol chemotherapy (PIPAC) every 4-6 weeks for 3 cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nab paclitaxel | Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2) |
| DRUG | Cisplatin | 10.5 mg/m2 |
Timeline
- Start date
- 2020-11-11
- Primary completion
- 2023-12-12
- Completion
- 2024-12-01
- First posted
- 2019-06-27
- Last updated
- 2024-05-24
Locations
2 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT04000906. Inclusion in this directory is not an endorsement.